Regeneron Reports 37% Lower Risk of Death in Longer-Term Libtayo Trial Data
Regeneron reported nearly four-year follow-up from the Phase III C-POST trial, showing a 37% reduction in risk of death with Libtayo in CSCC.
Regeneron reported nearly four-year follow-up from the Phase III C-POST trial, showing a 37% reduction in risk of death with Libtayo in CSCC.